Yanina Grant-Huerta insider trades: Atara Biotherapeutics (ATRA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Yanina reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | ATRA | ↓ Sell | 2,414 | $9.13 | $22K | Direct | May 20, 2026 (2d) |
| Mar 2, 2026 | ATRA | ↓ Sell | 2,104 | $5.08 | $11K | Direct | Mar 4, 2026 (2d) |
| Nov 17, 2025 | ATRA | ↓ Sell | 1,804 | $13.19 | $24K | Direct | Nov 19, 2025 (2d) |
| Aug 18, 2025 | ATRA | ↓ Sell | 1,809 | $11.61 | $21K | Direct | Aug 20, 2025 (2d) |
| May 16, 2025 | ATRA | ↓ Sell | 2,218 | $6.76 | $15K | Direct | May 20, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ATRA insiders
Open-market trades in the last 12 months
About Yanina Grant-Huerta's insider trades
Yanina Grant-Huerta is Chief Accounting Officer at Atara Biotherapeutics (ATRA). Since May 16, 2025, Yanina has reported no open-market purchases and 5 sales worth $93K on SEC Form 4. In the last 12 months: 3 sales ($57K).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ATRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.